These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9660040)

  • 1. Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.
    Chojnowska-Jezierska J; Adamska-Dyniewska H
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):326-32. PubMed ID: 9660040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum-lipid reducing principles--possibilities for treatment. 5. Indications for nicotinic acid and nicotinic acid derivatives].
    Orö L
    Lakartidningen; 1970 Dec; 67():Suppl IV:63+. PubMed ID: 5511953
    [No Abstract]   [Full Text] [Related]  

  • 6. Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients.
    Müller D; Mehling H; Otto B; Bergmann-Lips R; Luft F; Jordan J; Kettritz R
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1249-54. PubMed ID: 17913971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Special recommendations for lipid-lowering treatment: efficacy and safety].
    Martinez TL; Nascimento HM
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():6-8. PubMed ID: 16400389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of aspirin on niacin-induced cutaneous reactions.
    Whelan AM; Price SO; Fowler SF; Hainer BL
    J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of niacin or nicotinic acid].
    Santos RD
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():17-9. PubMed ID: 16400392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial.
    Czaja AJ; Carpenter HA; Lindor KD
    Hepatology; 1999 Dec; 30(6):1381-6. PubMed ID: 10573515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and safety of immediate-release niacin in patients with ischemic cardiopathy. Experience of the Instituto Nacional de Cardiología "Ignacio Chávez"].
    Morato Hernández ML; Ichazo Cerro MS; Alvarado Vega AG; Zamora González J; Cardoso Saldaña GC; Posadas Romero C
    Arch Inst Cardiol Mex; 2000; 70(4):367-76. PubMed ID: 11075282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.